Entera Bio Ltd - Understand $entx stock

$ENTX Market Cap: $76.28 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$57.00K

TTM

Gross Margin

15.79%

TTM

Net Earnings

-$8.536M

TTM

Current Assets

$9.595M

Q2 2024

Current Liabilities

$1.294M

Q2 2024

Current Ratio

741.5%

Q2 2024

Total Assets

$10.04M

Q2 2024

Total Liabilities

$1.503M

Q2 2024

Book Value

$8.532M

Q2 2024

Cash

$9.056M

Q2 2024

P/E

-8.936

Sep 18, 2024 EST

Free Cash Flow

-$7.339M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	$0.00	$134.0K	$571.0K	$370.0K	$240.0K	$500.0K	$0.00	$0.00	$0.00
YoY Change	-100.0%	-76.53%	54.32%	54.17%	-52.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	$0.00	$134.0K	$571.0K	$370.0K	$240.0K	$500.0K	$0.00	$0.00	$0.00
Cost Of Revenue	$0.00	$101.0K	$373.0K	$210.0K	$210.0K
Gross Profit	$0.00	$33.00K	$198.0K	$160.0K	$30.00K
Gross Profit Margin		24.63%	34.68%	43.24%	12.5%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Selling, General & Admin	$4.430M	$7.253M	$5.690M	$4.890M	$4.280M	$2.840M	$8.580M	$2.720M	$1.590M
YoY Change	-38.92%	27.47%	16.36%	14.25%	50.7%	-66.9%	215.44%	71.07%
% of Gross Profit		21978.79%	2873.74%	3056.25%	14266.67%
Research & Development	$4.510M	$5.848M	$6.771M	$6.400M	$7.200M	$8.520M	$2.770M	$2.650M	$2.120M
YoY Change	-22.88%	-13.63%	5.8%	-11.11%	-15.49%	207.58%	4.53%	25.0%
% of Gross Profit		17721.21%	3419.7%	4000.0%	24000.0%
Depreciation & Amortization	$56.00K	$64.00K	$53.00K	$230.0K	$240.0K	$50.00K	$40.00K	$40.00K	$30.00K
YoY Change	-12.5%	20.75%	-76.96%	-4.17%	380.0%	25.0%	0.0%	33.33%
% of Gross Profit		193.94%	26.77%	143.75%	800.0%
Operating Expenses	$8.891M	$13.05M	$12.42M	$11.29M	$11.48M	$11.36M	$11.34M	$5.370M	$3.700M
YoY Change	-31.87%	5.11%	9.96%	-1.66%	1.06%	0.18%	111.17%	45.14%
Operating Profit	-$8.891M	-$13.02M	-$12.22M	-$11.13M	-$11.45M
YoY Change	-31.7%	6.55%	9.77%	-2.79%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Interest Expense	$31.00K	$83.00K	-$29.00K	$1.240M	$740.0K	$520.0K	$250.0K	$4.310M	-$450.0K
YoY Change	-62.65%	-386.21%	-102.34%	67.57%	42.31%	108.0%	-94.2%	-1057.78%
% of Operating Profit
Other Income/Expense, Net	$31.00K	$83.00K	-$29.00K	-$28.00K	-$80.00K	$30.00K	-$110.0K	-$140.0K	-$130.0K
YoY Change	-62.65%	-386.21%	3.57%	-65.0%	-366.67%	-127.27%	-21.43%	7.69%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Pretax Income	-$8.860M	-$12.93M	-$12.25M	-$11.20M	-$10.80M	-$10.30M	-$11.20M	-$1.200M	-$4.280M
YoY Change	-31.5%	5.62%	9.38%	3.67%	4.85%	-8.04%	833.33%	-71.96%
Income Tax	$29.00K	$137.0K	-$59.00K	$20.00K			$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$8.889M	-$13.07M	-$12.19M	-$11.22M	-$10.80M	-$10.30M	-$11.20M	-$1.200M	-$4.280M
YoY Change	-31.99%	7.25%	8.66%	3.85%	4.85%	-8.04%	833.33%	-71.96%
Net Earnings / Revenue		-9754.48%	-2134.33%	-3031.35%	-4500.0%	-2060.0%
Basic Earnings Per Share	$0.31	$0.45	$0.47
Diluted Earnings Per Share	-$0.31	$0.45	-$466.3K	-$541.8K	-$888.9K	-$898.8K	-$985.9K	-$100.8K	-$359.7K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Cash & Short-Term Investments	$11.02M	$12.31M	$24.89M	$8.590M	$15.19M	$11.52M	$11.75M	$4.160M	$1.210M
YoY Change	-10.48%	-50.55%	189.78%	-43.45%	31.86%	-1.96%	182.45%	243.8%
Cash & Equivalents	$11.02M	$12.31M	$24.89M	$8.590M	$15.19M	$7.510M
Short-Term Investments					$0.00	$4.020M	$10.00K	$0.00	$0.00
Other Short-Term Assets	$238.0K	$294.0K	$254.0K	$260.0K	$170.0K	$220.0K	$670.0K	$1.270M	$700.0K
YoY Change	-19.05%	15.75%	-2.31%	52.94%	-22.73%	-67.16%	-47.24%	81.43%
Inventory
Prepaid Expenses
Receivables	$0.00	$246.0K	$183.0K	$260.0K	$280.0K	$730.0K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$11.26M	$12.85M	$25.33M	$9.110M	$15.64M	$12.47M	$12.42M	$5.430M	$1.900M
YoY Change	-12.39%	-49.27%	178.04%	-41.75%	25.42%	0.4%	128.73%	185.79%
Property, Plant & Equipment	$488.0K	$229.0K	$395.0K	$550.0K	$460.0K	$220.0K	$210.0K	$200.0K	$190.0K
YoY Change	113.1%	-42.03%	-28.18%	19.57%	109.09%	4.76%	5.0%	5.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$20.00K	$49.00K	$263.0K	$50.00K
YoY Change	-59.18%	-81.37%	426.0%
Total Long-Term Assets	$508.0K	$278.0K	$658.0K	$1.150M	$1.060M	$870.0K	$860.0K	$860.0K	$850.0K
YoY Change	82.73%	-57.75%	-42.78%	8.49%	21.84%	1.16%	0.0%	1.18%
Total Assets	$11.77M	$13.13M	$25.99M	$10.26M	$16.70M	$13.34M	$13.28M	$6.290M	$2.750M
YoY Change
Accounts Payable	$83.00K	$17.00K	$166.0K	$160.0K	$330.0K	$470.0K	$600.0K	$50.00K	$350.0K
YoY Change	388.24%	-89.76%	3.75%	-51.52%	-29.79%	-21.67%	1100.0%	-85.71%
Accrued Expenses	$1.008M	$1.324M	$2.980M	$1.070M	$1.140M		$1.210M	$450.0K	$350.0K
YoY Change	-23.87%	-55.57%	178.5%	-6.14%			168.89%	28.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due				$190.0K	$180.0K		$0.00	$9.890M	$0.00
YoY Change				5.56%			-100.0%
Total Short-Term Liabilities	$1.091M	$1.341M	$3.161M	$3.270M	$4.590M	$1.790M	$2.020M	$10.54M	$800.0K
YoY Change	-18.64%	-57.58%	-3.33%	-28.76%	156.42%	-11.39%	-80.83%	1217.5%
Long-Term Debt	$0.00	$0.00	$0.00	$240.0K	$120.0K	$0.00	$37.35M	$15.87M	$21.12M
YoY Change			-100.0%	100.0%		-100.0%	135.35%	-24.86%
Other Long-Term Liabilities	$288.0K	$32.00K	$261.0K	$80.00K	$70.00K	$1.440M	$5.470M	$5.120M	$6.520M
YoY Change	800.0%	-87.74%	226.25%	14.29%	-95.14%	-73.67%	6.84%	-21.47%
Total Long-Term Liabilities	$288.0K	$32.00K	$261.0K	$320.0K	$190.0K	$1.440M	$42.82M	$20.99M	$27.64M
YoY Change	800.0%	-87.74%	-18.44%	68.42%	-86.81%	-96.64%	104.0%	-24.06%
Total Liabilities	$1.379M	$1.373M	$3.422M	$3.600M	$4.780M	$3.230M	$44.84M	$31.53M	$28.43M
YoY Change	0.44%	-59.88%	-4.94%	-24.69%	47.99%	-92.8%	42.21%	10.9%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021
Basic Shares Outstanding	29.01M shares	28.81M shares	26.13M shares
Diluted Shares Outstanding	29.01M shares	28.81M shares	26.13M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $76.282 Million

About Entera Bio Ltd

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. The firm developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

Industry: Biological Products, (No Diagnostic Substances) Peers: Chemomab Therapeutics Ltd Collplant Biotechnologies Ltd Protalix Biotherapeutics Inc Evogene Ltd